Take the Money and Run in This Biotech

Following two FDA rejections and two sell signals, it's time to cash out of Gilead Sciences


Gilead Sciences (NASDAQ:GILD) — On Nov. 19, with the stock trading near $37.50, the Trade of the Day recommended it, saying, “This large-cap biotech is well positioned to gain market share.”

The stock gapped up to a new high following positive results from a study for its Hepatitis C treatment. However, Gilead suffered two setbacks this week when the FDA declined to approve two of its HIV drugs.

With GILD up 35% from our initial buy point, the FDA rejections coupled with the Collins-Bollinger Reversal (CBR) sell signal last week and an MACD sell signal, tell us that it’s time to cash in the profits on GILD.

However, this high-quality biotech is not a short-sale recommendation. In fact, if the stock were to pull back to support below $43, it would again be a candidate for our buy list.

GILD Chart
Click to Enlarge

Trade of the Day Chart Key

Article printed from InvestorPlace Media, http://investorplace.com/2013/05/trade-of-the-day-gilead-sciences-nasdaq-gild-3/.

©2016 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.